Answers are grounded in this paper and cite their sources.
We read with great interest the much-anticipated vancomycin therapeutic monitoring guideline published in the Journal.1 As expected, trough-only monitoring of vancomycin levels with a target concentration of 15 to 20 μg/mL for invasive methicillin-resistant Staphylococcus aureus (MRSA) infections is no longer recommended. The revised recommendation is for an area under the curve (AUC)–based approach, assuming a MRSA minimum inhibitory concentration (MIC) of ≤1 μg/mL that targets an AUC/MICBMD ratio of 400 to 600, due primarily to data demonstrating less nephrotoxicity compared to trough-based monitoring.2 Several different AUC-based methods are recommended, with the preferred strategy utilizing Bayesian software programs. While the clinical aspects of AUC-based dosing of vancomycin are well documented, there are many practical considerations to widespread change in vancomycin monitoring that involve logistical challenges and financial implications.3 Some important questions include: Our research group wanted to understand what characteristics are related to a transition to AUC-based dosing and monitoring since guideline publication. We surveyed the American College of Clinical Pharmacy’s Critical Care and Infectious Diseases Practice and Research Networks in May/and June 2020. The networks’ listservers comprise approximately 4,000 national and international members who represent varied practice settings. Participants received a 15-question survey on demographic factors, providers responsible for vancomycin-based dosing, and current and/or future plans for transition to AUC-based dosing and monitoring.
No takes yet. Share an insight, caveat, or question.
Bland et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: